No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Preserved ratio impaired spirometry (PRISm) represents a distinct lung function impairment linked to systemic inflammation and cardiometabolic risk. Cardiometabolic multimorbidity (CMM) was defined as ≥2 incident conditions (cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), stroke), This study aimed to examined the associations between baseline PRISm and incident CMM and its components in the UK Biobank cohort.
We analyzed baseline and follow-up data from participants excluding baseline CVD, T2DM, or stroke with valid spirometry. Participants were classified as three groups based on pre-bronchodilator lung function: normal group (defined as FEV₁ ≥80% predicted with FEV₁/FVC ≥0.70), PRISm (defined as FEV₁ ≥80% predicted with FEV₁/FVC ≥ 0.70), or airway obstruction (AO)(defined as FEV₁/FVC < 0.70). Incident CMM was ≥2 incident conditions (CVD, T2DM, stroke) in follow-up. Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) was used to analyze the associations between baseline PRISm and incident CMM and its components: Model 1 (age, sex, Townsend deprivation index, education); Model 2 (+ BMI, current smoking, drinking status); Model 3 (+ LDL-C, HDL-C, total cholesterol, systolic blood pressure, HbA1c). Restricted cubic spline (RCS) analyses examined dose-response relationships for continuous lung function measures and incident CMM.
236,132 participants (normal group: n=187,515, 79.4%; PRISm group: n=15,462, 6.6%; AO group: n=33,155, 14.0%) were enrolled in analysis. PRISm (vs. normal) showed markedly elevated incident CMM risk in fully adjusted models: HR 1.86 (95% CI 1.63–2.12, P<0.001), which was stronger than AO: HR 1.57 (1.41–1.76, P<0.001). PRISm associations were particularly pronounced for T2DM (HR 1.19, 1.11–1.27) compared to AO (HR 1.09, 1.03–1.16), with robust elevations also for CVD (PRISm HR 1.53, 1.43–1.64; AO HR 1.45, 1.38–1.53) and stroke (PRISm HR 1.33, 1.20–1.47; AO HR 1.21, 1.12–1.30, all P<0.001). RCS analyses confirmed significant non-linear inverse dose-response relationships between lung function and incident CMM.
PRISm may serve as an early, modifiable marker for cardiometabolic risk, advocating for combined pulmonary-cardiometabolic screening and targeted prevention.